Co-pathological connected primary neurons in a microfluidic device for Alzheimer studies

Biotechnology and Bioengineering

Volumn 108, Issue 9, 2011, Pages 2241-2245

  Kunze, Anja ^a   Meissner, Robert ^a   Brando, Serena ^a   Renaud, Philippe ^a  

^a EPFL   (Switzerland)

Author keywords

Chemical gradient; Co pathology; Hyperphosphorylated Tau; Microfluidic device; Okadaic acid; Primary neural cell culture

Indexed keywords

CHEMICAL GRADIENTS; CO-PATHOLOGY; HYPERPHOSPHORYLATED; MICROFLUIDIC DEVICE; NEURAL CELLS; OKADAIC ACID;

CELL PROLIFERATION; CELLS; FLUIDIC DEVICES; MICROFLUIDICS; NEURODEGENERATIVE DISEASES; NEURONS; PHOSPHORYLATION;

CELL CULTURE;

OKADAIC ACID; SYNAPTOPHYSIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; BRAIN NERVE CELL; CELL COMPARTMENTALIZATION; CELL POPULATION; EMBRYO; IMMUNOCYTOCHEMISTRY; LETTER; MICROFLUIDIC ANALYSIS; MICROTUBULE; MOLECULAR MECHANICS; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NERVE CELL NETWORK; NERVE FIBER GROWTH; NONHUMAN; PERFUSION; PROTEIN PHOSPHORYLATION; RAT; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; CELLS, CULTURED; CEREBRAL CORTEX; CYTOLOGICAL TECHNIQUES; MICROFLUIDIC ANALYTICAL TECHNIQUES; MODELS, NEUROLOGICAL; NERVE DEGENERATION; NEURONS; OKADAIC ACID; PHOSPHORYLATION; RATS; RATS, WISTAR; TAU PROTEINS;

EID: 79960473407     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23128     Document Type: Letter

References (25)

1. Arias C, Sharma N, Davies P, Shafit-Zagardo B. 1993. Okadaic acid induces early changes in microtubule-associated protein 2 and tau phosphorylation prior to neurodegeneration in cultured cortical neurons. J Neurochem 61(2): 673-682.
2. Baig S, van Helmond Z, Love S. 2009. Tau hyperphosphorylation affects Smad 2/3 translocation. Neuroscience 163(2): 561-570.
3. Ballatore C, Lee VM, Trojanowski JQ. 2007. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8(9): 663-672.
4. Brandt R, Hundelt M, Shahani N. 2005. Tau alteration and neuronal degeneration in tauopathies: Mechanisms and models. Biochim Biophys Acta (BBA)-Mol Basis Dis 1739(2-3): 331-354.
5. Delacourte A. 2008. Tau pathology and neurodegeneration: An obvious but misunderstood link. J Alzheimers Dis 14(4): 437-440.
6. Horn D, Levy N, Ruppin E. 1996. Neuronal-based synaptic compensation: A computational study in Alzheimer's disease. Neural Comput 8(6): 1227-1243.
7. Krinke D, Jahnke H-G, Mack TGA, Hirche A, Striggow F, Robitzki AA. 2010. A novel organotypic tauopathy model on a new microcavity chip for bioelectronic label-free and real time monitoring. Biosens Bioelectron 26(1): 162-168.
8. Kunze A, Giugliano M, Valero A, Renaud P. 2010. Micropatterning neural cell cultures in 3D with a multi-layered scaffold. Biomaterials 32(8): 2088-2098.
9. Millet LJ, Stewart ME, Nuzzo RG, Gillette MU. 2010. Guiding neuron development with planar surface gradients of substrate cues deposited using microfluidic devices. Lab Chip 10(12): 1525-1535.
10. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. 2006. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65(7): 631-641.
11. Palop JJ, Chin L, Mucke L. 2006. A network dysfunction perspective on neurodegenerative diseases. Nature 443(7113): 768-773.
12. Pariente J, Cole S, Henson R, Clare L, Kennedy A, Rossor M, Cipoloti L, Puel M, Demonet J, Chollet F, Frackowiak RS. 2005. Alzheimer's patients engage an alternative network during a memory task. Ann Neurol 58(6): 870-879.
13. Pearce TM, Williams JC. 2006. Microtechnology: Meet neurobiology. Lab Chip 7: 30-40.
14. Savioz A, Leuba G, Vallet PG, Walzer C. 2009. Contribution of neural networks to Alzheimer disease's progression. Brain Res Bull 80(4-5): 309-314.
15. Shamloo A, Heilshorn SC. 2010. Matrix density mediates polarization and lumen formation of endothelial sprouts in VEGF gradients. Lab Chip 10(22): 3061-3068.
16. Small DH. 2008. Network dysfunction in Alzheimer's disease: Does synaptic scaling drive disease progression? Trend Mol Med 14(3): 103-108.
17. Sun X, Cole GM, Chu T, Xia W, Galasko D, Yamaguchi H, Tanemura K, Frautschy SA, Takashima A. 2002. Intracellular A[beta] is increased by okadaic acid exposure in transfected neuronal and non-neuronal cell lines. Neurobiol Aging 23(2): 195-203.
18. Taylor AM, Jeon NL. 2010. Micro-scale and microfluidic devices for neurobiology. Curr Opin Neurobiol 20(5): 640-647.
19. Taylor AM, Dieterich DC, Ito HT, Kim SA, Schuman EM. 2010. Microfluidic local perfusion chambers for the visualization and manipulation of synapses. Neuron 66(1): 57-68.
20. Togo T, Akiyama H, Iseki E, Uchikado H, Kondo H, Ikeda K, Tsuchiya K, de Silva R, Lees A, Kosaka K. 2004. Immunohistochemical study of Tau accumulation in early stages of Alzheimer-type neurofibrillary lesions. Acta Neuropathol 107(6): 504-508.
21. Wang J-z, Tung YC, Wang Y, Li XT, Iqbal K, Grundke-Iqbal I. 2001. Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett 507(1): 81-87.
22. Wang J, Ren L, Li L, Liu W, Zhou J, Yu W, Tong D, Chen S. 2009. Microfluidics: A new cosset for neurobiology. Lab Chip 9: 644-652.
23. Wimo A, Prince M. 2010. Alzheimer's Disease International, World Alzheimer Report 2010, The global economic impact of dementia. Karolinska Institutet, Stockholm, Sweden and Institute of Psychiatry, King's College London, UK.
24. Yoon SY, Choi JE, Yoon JH, Huh JW, Kim DH. 2006. BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration. Neurobiol Dis 22(2): 435-444.
25. Zhang Z, Simpkins JW. 2010. An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Res 1359: 233-246.